Comparison of the effects of 5-azauracil and 6-azauracil on behavior and brain pyrimidine synthesis in rats by Noth, Robert Henry
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
1967
Comparison of the effects of 5-azauracil and
6-azauracil on behavior and brain pyrimidine
synthesis in rats
Robert Henry Noth
Yale University
Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Noth, Robert Henry, "Comparison of the effects of 5-azauracil and 6-azauracil on behavior and brain pyrimidine synthesis in rats"
(1967). Yale Medicine Thesis Digital Library. 2993.
http://elischolar.library.yale.edu/ymtdl/2993

YALE 
MEDICAL LIBRARY 


Digitized by the Internet Archive 
in 2017 with funding from 
The National Endowment for the Humanities and the Arcadia Fund 
https://archive.org/details/comparisonofeffeOOnoth 

COMPARISON OF THE EFFECTS OF 5-AZAURACIL AND 6-AZAURACIL 
ON BEHAVIOR AND BRAIN PYRIMIDINE SYNTHESIS IN RATS 
by 
Robert Henry Noth 
A Thesis Submitted in 
Partial Fulfillment 
Of the Requirements for the 
Degree of 
Doctor of Medicine 
Yale University School of Medicine 
June 1967 

ACKNOWLEDGEMENTS 
I am indebted to Professor Robert E. HandSchumacher of the 
department of Pharmacology for his continuing enthusiastic support, 
inspiration, friendship, perceptive criticism, and for his generous 
donation of laboratory facilities. 
I am also grateful to the United States Public Health Service 
for their PHS GM-59-06 (Welch) Summer Fellowship, PHS 5T-4-CA- 
5012-07 (Welch)Summer Fellowship, and PIS GM-59 Training Grant 
which made it possible to do this research during the summers of 
1964-1966. 

TABLES OF CONTENTS 
Introduction . .  1 
Materials ..   15 
Methods    16 
Results and Discussion .  24 
Conclusions . 35 
Summary ..  42 
Tables  44 
Figures .. 49 
Bibliography.   55 

INTRODUCTION 
The administration of 6-azauracil (as-triazine-3,5-dione; 6-AzU) 
a decade ago to a group of patients with neoplastic disease was 
complicated by the unexpected appearance of signs of central nervous 
1,2,3 
system toxicity. Although this resulted in withdrawal of 
6-AzU from clinical use, the cause of the unusual neurological 
4 5 
syndrome has continued to be a subject of interest and research. 5 
In particular, the question has arisen whether the toxic effects on 
the central nervous system are inseparably connected to the known 
antimetabolic action of 6-AzU, or whether they are the result of 
some unknown action of the as_-triazine ring per se. ^ 
In human subjects with neoplastic disease, oral administration 
of 6-AzU in doses as small as 4.5 mg/kg/day resulted in the appear¬ 
ance of characteristic premonitory changes in the electroencephalo¬ 
gram after several days and lethargy, followed by somnolence, motor 
6 
abnormalities, psychic disturbances, and coma. The most common 
motor abnormality was hyperreflexia, but muscle weakness and twitching, 
incontinence, choreiform movements, and tremor were noted in some 
patients. Psychic disturbances occurred in only about half of the 
patients, and commonly included mental deterioration, hallucinations, 
and in some patients euphoria and toxic psychoses. About a quarter 
of the 44 subjects became semicomatose or comatose. All changes were 
slowly reversible on withdrawal of the drug. 
t 
■ 
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Several patients had convulsive seizures after withdrawal. 
Additional toxic effects included thrombocytopenia and leukopenia 
during the course of administration in several of the patients. The 
ribonucleoside of 6-AzU, 6-azauridine (6-AzUR) is a much more effec¬ 
tive cytostatic agent and neurological disturbances have not occurred 
with intravenous administration of as much as 600 mg/kg/day. However, 
oral administration of 6-AzUR to patients results in 80% absorption 
in the form of 6-AzU, presumably because of the action of intestinal 
7 8 flora, ’ and causes the acute onset within a day of the typical 
encephalopathy usually seen after administration of 6-AzU. Although 
intravenous 6-AzUR is almost completely without toxicity in patients, 
only partial remissions have been produced by it in several types of 
adult acute leukemias; experience with solid tumors has been less 
g 
encouraging. Intravenous 6-AzUR and oral administration of triacetyl- 
6-azauridine (21,3',5'-triacetyl-6-azauridine) have, however, been 
remarkably successful in producing remissions in severe psoriasis 
9 
and mycosis fungoides. Administered orally, triacetyl-6-azauridine 
results in sustained blood levels of 6-AzUR; 80% of the dose is 
excreted in the urine as 6-AzUR, 17% as the monoacetyl derivative, 
and only 3% as the unchanged triacetyl derivative.^ In a series of 
17 patients treated with this drug initially at 270 mg/kg/day for 
1 to 3 weeks and then reduced to 135 mg/kg/day and maintained for 
as long as 6 months, the only toxic manifestation was a mild to mod- 
. 9 
erate anemia. The neurotoxicity observed in two of these patients 
receiving triacetyl-6-azauridine by mouth was attributable to an impurity 
of 6-AzUR (0.6%). 
' 
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Comparison of these effects in human subjects to those in 
experimental animals is complicated by differences in route and rate 
of administration, and by problems of measurement of neurological 
variables. Some generalizations, however, can be made; the support¬ 
ing evidence for these will be reviewed subsequently. The general 
pattern of neurological response to 6-AzU in mice, rats, dogs, and 
cats resembles that observed in the human subjects; the animals 
become somnolent and comatose, and appear to develop both motor and 
behavioral abnormalities. The dose required to elicit these responses, 
however, is probably several orders of magnitude greater for the 
laboratory animals. Rats and mice also differ from human subjects 
in responding to intravenous 6-AzUR with neurological signs indis¬ 
tinguishable from those caused by 6-AzU. From studies using the 
intraventricular route of administration it appears that the ribo¬ 
nucleotide of 6-AzU, 6-azauridylic acid (6-AzUMP) is also neuro- 
4 
logically active. In both cats and human subjects the effects of 
small doses of 6-AzU appear to be cumulative over a period of days, 
being neurologically equivalent to a single large dose, but again, 
as with the above observations, quantitative aspects have not been 
studied in detail. 
The changes in the electroencephalogram are quite distinctive. 
Both in cats, mice, and rats and in human subjects these include 
reduction of fast wave activity, reduction of photic response, and 
O / 1 Q 
the appearance of large amplitude, spiking slow waves. ’ * In 
both groups these precede other neurologic changes. In cats and 
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rats this pattern appears within an hour after intraperitonea 1 injec¬ 
tion of 1 to 3 gm of 6-AzU/kg. The minimum amount, administered 
either acutely or in repeated doses, required to produce these changes, 
however, is probably less. Similar changes in the electroencephalogram 
4 
of cats results from intraventricular administration of 6-AzUR, but 
8 
no change occurs from intravenous 6-AzUR in patients. 
Novotny, e_t al. have carefully measured several parameters of 
central nervous system activity which have been useful in comparing 
the effects of 6-AzU and 6-AzUR in mice, but which unfortunately are 
of little help in com paring mice to patients. They found that 
when 6-AzU was administered in a single intraperitoneal injection, 
significant depression of exploratory activity occurred after 50 mg/kg; 
anticonvulsant activity, especially against nicotine appeared at 200 
to 400 mg/kg, analgesia at 700 mg/kg, motor incoordination at 900 mg/kg, 
loss of righting reflex at 1550 mg/kg, and death at 2200 mg/kg. 
6-AzUR by this route had the same effects, but at about 2 to 4 times 
the dose. No effect was noted on deconditioning of avoidance of 
electric shock. Morris and Glaser have measured the maze running 
ability of rats made ataxic by 1 gm of 6-AzU/kg and found no signi- 
O 
ficant deficit in speed or accuracy. The observation that somnolent 
patients appeared to be mentally clear after their attention was 
aroused may be related. 
The response to parenteral administration of 6-AzU by cats and 
dogs is similar to that of mice and rats; 0.7 to 1.2 g/kg caused 
muscular flaccidity and ataxia without loss of righting reflex. 
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In monkeys, however, no abnormalities of behavior or changes in the 
electroencephalogram were observed after oral administration of 180 
mg of 6-AzU/kg/day for 4 days. Although this dose is much greater 
than that causing toxicity in patients, it is small compared to that 
causing motor incoordination and electroencephalographic changes in 
mice. 
Injection of 6-AzUR and 6-AzUMP into a lateral or the fourth 
ventricle allows more direct comparison of their relative activity 
in brain tissue. With some differences, the resulting neurological 
syndrome resembles that observed clinically from 6-AzU. Intraventri¬ 
cular administration of these drugs has not been performed in human 
subjects. The evidence of Novotny, et_ aJL. suggests that in mice 
the relative activity of 6-AzUMP is greater than that of 6-AzUR, and 
that both may be more active than 6-AzU. The effects of direct intra¬ 
ventricular administration of 6-AzU, however, are not reported in the 
literature. Injection of 50 mg of 6-AzUR into the lateral cerebral 
ventricle of a cat (of unstated weight) caused motor incoordination. 
The concentration of 6-AztIR in various regions of the brain was 0.22 
to 0.74 micromoles/gm of wet tissue, while the concentration of 6-AzlJMP 
was 3 to 4% of this. Intraventricular injection of doses of 25 to 50 
mg of 6-AzUR/kg in cats caused motor incoordination, often preceded by 
outbursts of stereotyped movements, such as cleaning or shaking of the 
head, followed in thirty minutes by sleep. In rats a similar syndrome 
was observed at 5 to 12.5 mg of 6-AzUR/kg; outbursts of activity became 
progressively incoordinated, finally becoming a series of muscular jerks. 
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This was elicited by only 1 to 5 mg of 6-Azump. Larger doses of 
these drugs usually caused only general depression. The early 
period of activity observed after intraventricular, but not intra- 
peritoneal, injection may just be a function of the region of the 
brain effected. Administration of 1 or 10 mg of 6-AzUR into the 
fourth ventricle of cats each day for three days caused the appear¬ 
ance of lethargy, unsteadiness on the feet, and after two days nystag¬ 
mus, extensor hypertonia, and myoclonic jerks. Whether or not this 
4 14 
occurred at both dosages is unclear. 5 In these cats the character¬ 
istic changes in the electroencephalogram developed later; this may 
be related to the particular site of injection which is some distance 
14 
from midbrain and forebrain structures. The response of these 
animals also closely resembles the response of patients to 6-AzU 
in that there was evidence of hyperactivity (myoclonic jerks) 
accompanied by lethargy and incoordination. In the above experiment 
assuming that 30 mg of 6-AzUR was administered during the 3 days, 
and that all of it remained in brain tissue as 6-AzUR or 6-AzUMP, 
the concentration of triazine would have been roughly 0.5 micromoles/gm 
An equivalent of 6-AzU entering the brain by the vascular route in 
rats would probably have caused only lethargy and a measurable 
decrease in exploratory activity. This suggests that 6-AzUR or 
6-AzUMP may be more active neurologically than 6-AzU. It may also 
be that particular centers are more important in producing the 
neurological effects, and that they are markedly effected by the 
ventricular administration. 
An unexplained observation in both patients and laboratory 
' 
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animals is that younger subjects are more sensitive to the triazines. 
This may in part be caused by the relatively smaller amount of body 
tissue as compared to brain tissue in young animals, or may be related 
to some biochemical or neurological difference in the developing 
nervous system. 
15-19 
The anti-neoplastic activity of 6-AzUR has been shown to 
result from conversion iai situ to 6-AzUMP which competitively inhibits 
19-22 
orotidylic decarboxylase. This same conversion and inhibition 
occurs after administration of 6-AzUR in brain tissue of cats and rats. 
4 
Koenig, et al., have shown that in cat brain 6-AzUR is several times 
23 
more rapidly converted to the nucleotide than is 6-AzU. Skold has 
measured the activity of the two enzymes responsible for these con¬ 
versions, uridine kinase and uridine phosphorylase, in extracts of 
mouse brain and has found a similar pattern, the uridine kinase 
being about three times more active. There was some variation in 
the ratio of the activities of these two enzymes in comparing other 
tissues of mice and rats, and extrapolation of the above three 
to one ratio to rat brain and human brain may be inaccurate. 
Further evidence of species variation is shown by the complete 
24 
absence of the uridine kinase in the protozoa Trypanosoma equiperdum. 
Other actions of the triazines need only be mentioned. The 
inhibition of polynucleotide phosphorylase by 6-AzUDP is of unknown 
. . . . , . 25,26 r . 
physiological importance. In cat brain, however, the percentage 
of the nucleotide which is phosphorylated to di- or tri-phosphates 
4 
is vanishingly small. The inhibition of the incorporation of 
amino acids into proteins reported to occur in pancreatic homogenates 
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26 is likewise of unknown significance. 
The relative uptake of the base and the ribonucleoside into 
brain tissue from the bloodstream under various conditions has 
not been extensively studied. In cats, after intravenous infusion 
of the test solution to achieve constant blood levels, the cerebro¬ 
spinal fluid to blood ratio during perfusion of the lateral ventricle 
with artificial cerebrospinal fluid was 0.013 for 6-AzUR, 0.43 for 
27 
6-AzU, and 0.57 for glucose. Comparison of the concetration of 
6-AzU and 6-AzUR in the brain after intraperitonea 1 administration 
of these drugs is not possible from old data because of the very low 
22 
uptake of the riboside by brain tissue. Blood levels of 6-AzUR 
28 
decrease very rapidly because of rapid excretion by the kidney. 
This is probably another factor contributing to the low uptake of 
the riboside by brain tissue. 
The metabolic fate of orotic acid is of central importance in 
this study. The biosynthesis de_ novo of orotic acid was first 
extensively studied in bacteria by Kornberg and Liebermann over a 
33 -36 
decade ago. The pathway in mammalian tissue is probably the 
37-40 
same, except that carboxymethyl hydantoin is not formed (Figure 1). 
Whether the orotic acid pathway is a major supplier of acid- 
soluble nucleotides in brain is obviously of importance; it is not 
the only source. The therapeutic effectiveness of the triazines 
probably depends on the wide variation of various tissues with 
respect to their dependence on the synthesis of pyrimidines da novo. 
Specifically, human neoplastic leukocytes and normal canine leukocytes 
are particularly sensitive to 6-AzUMP. In these tissues, the activity 
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of orotidylic acid decarboxylase is high. Probably the most con¬ 
vincing evidence of the degree of dependence of brain tissue on 
synthesis de novo is the previously mentioned study of Koenig, 
4 
et al. , in which 1 or 10 mg of 6-AzUR was administered into the 
fourth ventricle of two cats for 4 days and 0.112 micromoles of 
6-^C-orotic acid was given three hours before sacrifice; this 
caused the incorporation of the radioactive orotic acid into acid- 
soluble pyrimidines of the hindbrain to diminish by 78 and 97%. 
Most significantly, the acid-soluble pyrimidine pool had been de¬ 
creased by about 50%. Since the 6-AzUR was administered intra- 
ventricularly, the inhibition of pyrimidine synthesis in the liver 
was probably not significant, and exogenous pyrimidines were prob¬ 
ably available to the brain. That the neurological syndrome caused 
by the administration of 6-AzUR may itself cause depletion of the 
pool of acid-soluble nucleotides in the brain cannot at present be 
ruled out, but the changes in pyrimidine metabolism are consistent 
with the known mechanism of action of 6-AzUR in other tissues. An 
unexplained finding in Koenig's study was that despite 75 to 98% 
inhibition of the incorporation of radioactive orotic acid into KNA, 
the RNA pool size unchanged after 4 days. This suggests the possi¬ 
bility of preferential incorporation of pyrimidines, perhaps from 
the liver, into brain RNA. Alternatively, the apparent sparing of 
brain RNA may be a reflection of a relatively slow rate of turnover 
41 42 
of the RNA. Other studies by Koenig ’ show that radioactive 
orotic acid is actively incorporated into the RNA of neurons and 
oligodendroglia. Adams4- has compared incorporation of radioactive 

-10- 
orotic acid and radioactive uracil into the KNA of the brains of 
untreated young adult rats and comcludes that these brains utilize 
pyrimidines synthesized de novo for KNA synthesis. 
Although it is probably the case that acid-soluble pyrimidine 
nucleotides in the brain are formed largely from orotic acid, there 
are other potential sources. Radioactive uridine is rapidly incor¬ 
porated into uridylic acid and its derivatives in cat brain when 
orotidylic acid decarboxylase is inhibited by 6-AzUR.^ Geiger, ejt 
44,45 
al., have reported that the electrical activity of isolated, 
perfused brains of cats is prolonged by the addition of uridine and 
cytidine to the perfusion medium. In hereditary orotic aciduria, 
the genetic equivalent of 6-AzUMP blockade in human subjects, the 
neurological, as well as hematological, symptoms are markedly im- 
32 
proved by administration of uridine, though not by uracil. It 
has been shown in rats that both uridine kinase and uridine phosphory- 
lase, which convert uridine to uridylic acid and uracil to uridine 
respectively, are present in brain, but as in bone marrow and spleen, 
23 
in very low concentration compared to intestine. The local con¬ 
centration of these enzymes in the intestine, which receives exogen¬ 
ous uracil and uridine from the diet, may be related to the good 
46 
tolerance of the intestine during administration of 6-AzUR. The 
ability of convert orotic acid to uridylic acid, on the other hand, 
was greatest in the spleen. In mice receiving 250 mg of 6-AzUR/day 
for a month the spleen became smaller, the number of lymphocytes and 
47 lymphoblasts decreased, and atypical mitotic activity appeared. 
However, in this group of mice, there were also marked changes in 
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the intestinal mucosa, and it is therefore obviously unsafe to 
generalize that tissues with active synthesis of pyrimidines from 
orotic acid and with relatively low uridine kinase activity are 
more severely effected by 6-AzUR. Although uracil incorporation 
into the acid-soluble pyrimidine nucleotides of rat brain is rela¬ 
tively slow, this may be an artifact of measurement caused by the 
relatively large pool of uracil, as pointed out by Canellakis in 
29 
his studies with rat liver. 
In order to estimate the degree of blockade of orotidylic 
acid decarboxylase using the method described below, it is important 
to know that the only pathway utilized for the metabolism the 
radioactive orotic acid is toward synthesis of uridylic acid. The 
equilibrium of the reaction catalyzed by purified dihydroorotic acid 
dehydrogenase of Zymobacterium oroticum strongly favors formation of 
34 
dihydroorotic acid. A number of observations suggest, nevertheless, 
48 
that this pathway is not used by mammalian tissues in vivo; in liver, 
carbamyl-L-aspartate is catabolized only one-fifth as rapidly as orotate 
both 5-azaorotic acid and 6-AzUMP can almost completely block catabolism 
of orotic acid; in tissue homogenate studies in vitro, 5-phosphoribosy1- 
1-pyrophosphate in the medium is necessary for any catabolism of orotic 
acid. In the brain of the cat it is also possible to decrease the 
incorporation of radioactive orotic acid into acid-soluble derivatives 
by as much as 98% by administration of 6-AzUR. If alternative path¬ 
ways were available for the metabolism of orotic acid, radioactivity 
should have appeared in the acid-soluble fraction. On the other hand, 
- 
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one study has shown that the specific activity of uracil as compared 
to uridylic acid in rat brain (but not in rat liver) is signifi¬ 
cantly increased after the administration of radioactive orotic 
49 
acid. This suggests either that there is a heterogenous pool 
of UMP in the brain, or that orotic acid is directly converted to 
uracil. The amount of radioactive uracil derived directly from 
orotic acid was probably quantitatively unimportant in the present 
experiment (see below); however, the amount of uracil which was 
rapidly lost from brain tissue or rapidly converted into uridine, 
uridylic acid, or j3-alanine was not measured. 
The mechanisms controlling the metabolism of orotic acid have 
been studied in microorganisms and mammals. When Escherichia coli 
mutants with a block in pyrimidine synthesis are grown in a medium 
limited in pyrimidines, there is an increase in the production of 
32 
the enzymes catalyzing the synthesis of pyrimidines, probably 
because of the release of end-product repression. A mechanism of 
control known to be active in rat liver is inhibition of the activ¬ 
ity of aspartate transcarbamylase by various uridine and cytidine 
derivatives, deoxyribonucleosides, and purine deoxyribonucleotides.^ 
Dihydroorotase is also subject to some degree of inhibition by these 
52 
products. Orotidylic acid decarboxylase is inhibited by uridylic 
acid. An indication of the effectiveness of these mechanisms is 
the increase in the excretion of orotic acid from one milligram to 
more than 8 grams within several days in patients treated with 
6-AzUR. The accumulation of endogenous orotic acid in tissues after 
blockade by 6-AzUR would complicate the interpretation of studies 
. 
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utilizing radioactive orotic acid as a precursor. A large amount 
of endogenous orotic acid would dilute the radioactivity of the 
administered orotic acid, and the inhibition of the metabolism of 
orotic acid would appear falsely high. On the other hand, the 
mass effect of an increased amount of orotic acid would tend to 
accelerate its metabolism and to compete with the inhibitor, and 
the effectiveness of the inhibitor would appear falsely low. The 
concentration of orotidylic acid, the immediate precursor of uridylic 
acid, may also be similarly increased, since orotidine excretion in 
the urine of patients treated with 6-AzlXR is also markedly increased. 
The problem of dilution is probably not encountered in this study, 
however, since the amount of radioactive orotic acid is probably 
relatively great, and the time course short (see discussion below). 
Since brain tissue shows considerable dependence on the meta¬ 
bolism of orotic acid for its supply of pyrimidines, and since these 
reactions are strongly inhibited by administration of 6-AzU, it is 
4 5 
reasonable to connect the behavioral effects with this inhibition. 5 
Nevertheless, another dose-dependent effect of the triazines unre¬ 
lated to their antimetabolic activity is difficult to rule out. 
Because of the structural and pharmacological similarities of the 
triazines to barbiturates, a barbiturate-like effect has been 
6 11 
postulated. * Evidence suggesting this comparison will be dis¬ 
cussed later. The approach taken in the following experiment is 
the much easier task of demonstrating that equivalent inhibition of 
the metabolism of orotic acid (and therefore of pyrimidine synthesis) 
in the brain by another pyrimidine analog is not associated with 
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neurological signs. Another structural analog of uracil, 5-azauracil 
(svm-triazine-2.4-dione; 5-AzU), which has been shown to have anti- 
17 54 55 
tumor and antibacterial activity, 5 * is also capable of inhibiting 
56 
the metabolism of orotic acid. Although less extensively studied, 
5-AzU does not appear to cause abnormalities in the function of the 
central nervous system. 
The action of this symmetrical triazine is probably inhibition 
of both orotidylic acid decarboxylase and orotidylic acid pyrophos- 
phorylase. Using a par tide-free extract of mouse liver, Handschu- 
56 
macher"” has shown that release of from 7-"C-orotic acid was 
_3 
inhibited 78% by 2 x 10 M 5-AzU, and that at the same concentration 
14 14 
of 5-AzU release of CO^ from 7- C-orotidylic acid was also 
inhibited, but by only 47%. The mechanism of this action may be 
complex, however, since 5-AzU is to some extent metabolized like 
6-AzU,^ and in addition, the ring structure is unstable. In a pH 7.4 
buffer at 37° the base is hydrolyzed to N-formylbiuret and biuret 
58 
spontaneously. The N-formylbiuret is known to inhibit dihydroorotase 
in Escherichia coli and to have significant antibacterial and anti- 
59 
mitotic effects. Another action of 5-AzU is inhibition of uridine 
60 
phosphorylase and deoxyuridine phosphorylase. During the three 
hour course of the following experiments, however, non-enzymatic 
degradation of 5-AzU would have been only 10 to 15%, and the con¬ 
centrations of the metabolites required for inhibition are large. 
14, 
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MATE RIALS 
The solvents used in paper chromatography were prepared 
as follows: (1) n-butanol, acetic acid, and water, 5:1:2; '(2) 
n-butanol, pyridine, and water, 1:1:1; (3) iso-butyric acid, 2N 
ammonium hydroxide, and water, 85:1.3:15; (4) n-butanol and water, 
86:14; and (5) ethanol, concentrated ammonium hydroxide, and water, 
75:5:25. A descending solvent front of 40 to 50 cm on Whatman #3 
paper was used for all studies. 
The 5-AzU and 6-AzU were obtained from the Cancer Chemotherapy 
National Service Center. Chromatography in solvent systems 1,2, 
and 3 showed no ultraviolet-absorbing impurities. The 2-^C-5-aza- 
orotic acid was prepared by Dr. P. K. Chang, the 2-^C-orotic acid 
was obtained from New England Nuclear Corp., Boston, Mass.,and the 
14 
2- C-6-azauracil was obtained from Volk Radiochemical Company, 
Burbank, Calif. Chromatography in solvent systems 1 and 2 indicated 
that the purity of these radioactive compounds was at least 97 to 
98%. 
Radioactivity of solutions and papers was assayed by liquid 
61 
scintillation as previously described. 
. 
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METHODS 
General 
All experimental animals were Charles River Sprague-Dawley 
white male rats weighing between 55 and 70 gm. In all experiments 
the freshly-prepared, warm solutions of 5-AzU or 6-AzU were admin¬ 
istered by intraperitoneal injection of three equally divided doses 
one-half hour apart, totaling 2.0 gm/kg of body weight. For purposes 
of discussion, the time elapsing after injection is always figured 
from the final injection. The pKa1s of 5-AzU and 6-AzU are 6.7 
and 7.0 and by calculation the isotonic pH 7.4 solutions contain 
19.1 and 20.4 mg of triazine/ml, and 0.141 and 0.129 ml of IN NaOH/ml 
respectively. These solutions were prepared and their pH adjusted 
to 7.4 with small amounts of NaOH. Peritoneal washings showed less 
than 10% of either drug remaining free in the peritoneum one hour 
after the injections. Control animals received warm 0.9% saline, 
200 ml/kg of body weight in three divided doses one-half hour apart. 
Behavioral parameter 
The 6-azauracil, 5-azauracil, and saline were administered 
above to six animals and the righting reflex was measured every 15 
minutes. Loss of the righting reflex was considered complete when 
animals did not right themselves within 30 seconds after being placed 
back down on a hard surface. Activity, muscle tone, and coordination 
- 
-17- 
were observed at 10 minute intervals but not quantitated in the 
three groups. 
Tissue distribution 
(a) 5-AzU. 2-^"C-5-azauracil was prepared from 2-^C-5-aza- 
orotic acid by treatment with 0.5 N HC1 for 30 minutes at 50°. The 
main product of the reaction was shown to have the same Rf as 5-AzU 
in solvent systems 2,4, and 5. It was purified by isotopic dilution 
with 5-azauracil and recrystallization from boiling methanol. Chromato 
graphic analysis in solvent 1 showed 99.1% of the radioactivity in 
the ultraviolet-absorbing 5-azauracil spot, and less than 0.3% in 
the regions known to contain the decomposition products of 5-azauracil. 
14 
Isotonic pH 7.4 solutions containing the C-labelled compounds were 
prepared and administered as described above. The animals were 
sacrificed at 1,2, and 4 hours by withdrawal of blood from the abdom¬ 
inal aorta under ether anaesthesia. Solid tissues were homogenized 
with 5 volume of 0.5 N perchloric acid and blood homogenized with 3 
volumes of 5% trichloroacetic acid. After centrifugation for 15 
minutes at 4000 x g the radioactivity of the supernatant solution 
was measured. Respiratory gases were analyzed for in one 
animal for 4 hours. Urine was collected and analyzed by paper 
chromatography with solvents 1 and 5. 
(b) 6-AzU. The procedure was identical to the above for 5-AzU 
except with the four animals sacrificed at 2 hours. From these animals 
a pH 7.0 extract of whole brain was prepared as described below, using 
5 volumes of 5 N perchloric acid at 0°. This was lyophilized, recon- 
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stituted with sufficient water to dissolve the solids at 40°, and 
aliquots containing about 1700 counts per minute were spotted on 
paper. Paper chromatography in solvent systems 1,2, and 3 and grad¬ 
ient elution chromatography using Dowex 1x4 200 mesh columns with 
a 2 N ammonium formate eluant was also performed. The single 
radioactive peak from this column was lyophilized, the resulting 
white solid dissolved in water, and its identity with 6-AzU confirmed 
using solvents 1,2, and 3. The acid-insoluble residue containing 
the KNA was washed an additional 6 times with 5 volumes of 0.5 N per- 
chloric acid. Both the fifth and sixth wash were free of radioactivity. 
Following successive dehydration with 10 volumes of 95% ethanol, abso¬ 
lute alcohol, a boiling mixture of 1 part absolute alcohol and 3 parts 
ether, and finally anhydrous ether, a fine white powder was obtained. 
This was dissolved in 3.0 ml of 0.3 N NaOH/100 milligrams of powder 
and incubated at 37° for 24 hours. Neutralization with a slight 
excess of 12 N HC1 to about pH 6, addition of 1 volume of absolute 
alcohol, and centrifugation in the cold yielded a clear supernatant 
fluid which was assayed for radioactivity (150 minutes for each sample) 
and ultraviolet absorption at 260 and 280 millimicrons. 
Tissue slices 
Untreated rats were anaesthetized with ether, exsanguinated via 
the abdominal aorta, and the brain rapidly excised. Tissue slices 
were taken from the cerebral cortex such that each hemisphere yielded 
about 4 slices of gray tissue weighing 125 mg. The slices were imme¬ 
diately transferred to rubber capped center-wall flasks containing 
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14 5 
0.1 micromoles of 7- C-orotic acid, 8 x 10 counts per minute 
62 
per ml, and Krebs III solution to a final volume of 2.0 ml. The 
slices from one hemisphere served as a control; 5-AzU, 6-AzU, or 
6-AzUR were added to the other. The center-we 11 contained 0.2 ml 
of 2 N NaOH. Flasks were incubated with shaking for 30 minutes at 
37° and the reaction stopped by injection of 0.5 ml 6 N perchloric 
acid. The flasks were shaked for an additional 15 minutes to assure 
14 
the complete release of C02« Reagent blanks were treated similarly. 
The NaOH in the center well was assayed for radioactivity. If incuba¬ 
tions were performed for 60 minutes instead of 30 minutes, the release 
14 
of C02 was increased by only 50%, thus indicating a decreased reaction 
rate with longer incubation periods. Two rats received the standard 
pretreatment with 5-AzU and 6-AzU, and after 2 hours tissue slices 
from each hemisphere were incubated as above to determine the 
effect of treatment in vivo on activity _in vitro. 
14 
Metabolism of 2- C-orotic acid in vivo 
The following procedure was performed four times, each time 
on a group of six rats treated with 5-azauracil, 6-azauracil, or 
saline. One hour after the third injection of the triazine or 
saline each rat was lightly anaesthetized with ether and 0.05 ml 
14 
+ 0.002 ml of 2- C-orotic acid, 9.0 micromoles/ml, 30 microcuries/ml 
was injected into the cisterna magna through a #27 gauge needle 
fitted with a metal disk 3/16 of an inch from the tip. Animals 
treated with 5-AzU or saline rapidly awakened after or during the 
✓ 
twenty second injection period, but those treated with 6-AzU, responding 
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only sluggishly to the noxious stimulus of the ether in the first 
place, remained unresponsive and tachypneic until the time of 
sacrifice one hour later. In nine of ten control animals an 
injection of Evans Blue dye was distributed throughout the subarach¬ 
noid space. In the radioactivity studies, of the twenty four ani¬ 
mals injected with ratioactive orotic acid, three were excluded, 
one because of leakage at the injection site, and two because the 
total recovery of acid-soluble radioactivity was over 5 standard 
deviations lower than the mean for their group. 
One hour after the injection of radioactive orotic acid, the 
rats were anaesthetized with ether and rapidly exsanguinated via 
the abdominal aorta. The brain was removed immediately, cut into 
six pieces to open the ventricles, washed three times in ten 
volumes of ice-cold 0.9% saline, blotted, weighed, homogenized in 
two volumes of 0.5 N perchloric acid at 0°, centrifuged for fifteen 
minutes at 4000 x g at 0°, and the clear supernatant fluid removed. 
A second supernant fraction was similarly prepared from the residue, 
combined with the first, and assayed as the acid-soluble fraction. 
This was neutralized with 5 N potassium hydroxide, weighed in tared 
tubes to determine the volume, and the total radioactivity deter¬ 
mined by scintillation counting. The acid-insoluble residue was 
washed at 0° five times with 10 volumes of water (first two groups) 
or 10 volumes of 0.5 N perchloric acid (second two groups). In 
three of the four groups of 6 animals the final wash contained no 
radioactivity; one group was discarded because of inadequate wash¬ 
ing. The dried, defatted residue containing the DNA,RNA and protein 
' 
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was hydrolyzed with sodium hydroxide as described above. The amount 
of incorporation of radioactivity into RNA per mg of dried, defatted 
tissue was calculated, and compared to the control in each group. 
To measure incorporation into DNA, the residue from the first 
hydrolysis was rehydrolyzed with the same volume of 0.3 N sodium 
o 
hydroxide for four hours at 37 , and reprecipitated again by 
neutralization and addition of alcohol. This residue was washed 
three times with 1% trichloroacetic acid at 0° and heated at 85° 
for 30 minutes in 5% trichloroacetic acid. After centrifugation, 
the radioactivity of the supernatant solution was measured. 
The liver was homogenized in 2 volumes of cold 0.5 N perchloric 
acid, centrifuged at 4000 x g for 15 minutes at 0°, and the radio¬ 
activity of the supernatant fraction measured. Blood was treated 
similarly except that 3 volumes of 5% trichloroacetic acid was used 
for extraction. Urine was collected under wire screens at the bot¬ 
tom of beakers and the radioactivity determined. 
Aliquots of the acid-soluble extract from the brain were 
analyzed in two ways; by isotopic dilution with carrier orotic acid 
after hydrolysis with acid to convert orotidine and orotidylic acid 
to orotic acid; and by paper chromatography. 
(a) Isotopic dilution. One ml aliquots were treated with 6 N 
o 
hydrochloric acid at 100 for 15 minutes in stoppered tubes to 
completely hydrolyze orotidylic acid and orotidine to orotic acid. 
The kinetics of this hydrolysis were studied using a Spectrocord 
500 recording spectrophotometer. Orotic acid (50 mg) was added, 
dissolved by the addition of NaOH, and precipitated again by the 
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addition of HC1. The precipitate was crystallized twice from 
boiling water, yielding 15 to 20 mg of fine white powder. This 
purified orotic acid was dissolved in 1 N sodium hydroxide and 
aliquots were taken for determination of radioactivity and absorp¬ 
tion of ultraviolet light at 260 millimicrons and 280 millimicrons. 
From these data the total concentration of orotic acid, orotidine, 
and orotidylic acid in the perchloric acid extract could be calcu¬ 
lated. The purity of the orotic acid was checked in one group by 
a third recrystallization; the specific activity remained unchanged. 
Paper chromatography with solvent systems 1 and 2 showed 90% of the 
radioactivity contained in the wide ultraviolet-absorbing band of 
orotic acid and 10% non-specifically distributed. 
(b) Paper chromatography. A total of twelve samples from 
the four groups was chosen for the more extensive analysis. The 
acid-soluble extract after adjustment to pH 7 was resolved satis¬ 
factorily by two chromatographic systems, 1 and 2. In addition, 
aliquots were hydrolyzed by treatment with 6 N HC1 at 100° for 15 
minutes and also by treatment with 1 N HC1 for 30 minutes. The 
hydrolyzed extracts were evaporated to dryness in vacuo at 40°, 
reconstituted with water, and analyzed by chromatography with sol¬ 
vent 2. The consistency of these results was confirmed for one 
sample in solvent system 3. For each chromatogram, 50 microliters 
of the sample was mixed with 25 micro liters of a solution containing 
orotidylic acid, orotidine, orotic acid, uridylic acid, uridine, 
and uracil at sufficient concentrations to be detectable by their 
ultraviolet absorption. The chromatograms were cut into 10 to 15 
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pieces, based on the positions of the authentic compounds. The 
radioactivity of the sections was determined by scintillation 
counting as previously described. 
Except when otherwise indicated, the standard deviation of 
the data is reported with each result. 
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RESULTS AND DISCUSSION 
Behavioral parameter 
After administration of 2 gm of 6-AzU/kg by intraperitoneal 
injection, rats lost the righting reflex within 30 to 60 minutes 
(after the third divided dose) and became unresponsive to corneal 
stimululation or to pinching of the foot. However, in later experi¬ 
ments, it was noticed that these rats did show some sluggish response 
to anaesthetization with ether. The range of time for complete 
recovery of the righting reflex was two to seven hours. In the rats 
treated with saline or 5-AzU there was no ataxia, flaccidity, de¬ 
crease in activity, or slowing of the righting reflex as was observed 
in those receiving 6-AzU. 
Tissue distribution 
In comparison with 6-AzU, the 5-AzU was very rapidly eliminated 
from the blood stream and achieved lower levels in the central ner¬ 
vous system (Table 2). The concentration of 5-AzU in tissues other 
than the brain dropped precipitously after the first hour. One 
hour after receiving the third divided dose of 2-^C-6-azauracil 
the concentration of radioactivity in the acid-soluble fraction of 
the brain was 3.1 micromoles/gm while that of the animals receiving 
2-^C-5-azauraci 1 was only 0.5 micromoles/gm. Of the radioactivity 
recovered from the animals receiving 6-AzU, most was unchanged 2-^C- 
6-AzU (see below). Because of the low specific activity, no attempt 
was made to determine the extent of the metabolism of radioactive 
5-AzU. 
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The poor penetration of 5-AzU into brain tissue may be partly ex¬ 
plained by its acidity. At pH 7.4 only 17% of the 5-AzU is present 
in the uncharged acid for, compared to 29% of 6-AzU. The marked 
drop in the blood concentration of 5-AzU during the second hour to 
about 10% of the one hour level may explain why the brain concen¬ 
tration failed to rise during this time. Plasma levels were not 
significantly higher than those of whole blood, suggesting that 
the compound freely permeates erythrocytes. Urine output seemed 
markedly less in the animals receiving 6-AzU than in the others, 
and was often not detectable. The total excretion of the radio¬ 
activity, presumably as 2-^C-6-AzU,^^ varied widely from 3% to 
44% of the injected dose after 2 hours. Although the concentrations 
of 6-AzU in the brain in the animals sacrificed after 2 hours only 
varied by 8%, the range of concentrations in other tissues was as 
great at 50%. The urinary excretion of 5-AzU after 2 hours was only 
42% of the injected radioactivity, but the bladder urine was not 
recovered from this animal. Chromatography of this urine using 
solvent system 1 showed that 60% of the 5-AzU was excreted unchanged. 
The total recovery of the respiratory ^CC^ from the animal treated 
with 5-AzU was less than 0.4% of the injected dose after 2 hours. 
The results from both paper and column chromatography of the 
perchloric acid extract of the brain of one of the four animals 
sacrificed after 2 hours indicate that the rate of metabolism of 
the administered 6-AzU is very slow in brain tissue. Chromatographic 
analysis of the acid-soluble extract in solvent systems 1 and 3 
allowed good resolution of 6-AzU, 6-AzUR, 6-AzUMP, and glyoxylic 
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acid semicarbazone, the primary metabolites of 6-AzU, and re¬ 
vealed a single radioactive peak. The main peak of the acid- 
soluble extract was split in solvent 2. This splitting, however, 
was caused by the interference of salts and other compounds in 
the neutralized acid-soluble extract, since when the single peaks 
from the other two chromatograms were eluted and analyzed using 
solvent system 2, they moved as a single peak. This major peak 
contained 97.5% of the total radioactivity of the perchloric acid 
extract and had Rf's identical with those of 6-AzU. The other meta¬ 
bolites were present in low concentration: 6-AzUR, 0.7% + 0.2%; 
6-AzUMP, 0.5%+ 0.2%; glyoxylic acid semicarbazone, 0.4% + 0.2%. 
(The mean and the range of the two values from chromatographic 
analysis in solvent systems 1 and 3 are indicated). These values 
represent upper limits of activity for the respective metabolites. 
Recovery of radioactivity after column chromatography was 98%; only 
one peak was detected. Paper chromatography in solvent systems 1, 
2, and 3 showed 98.0 + 1.7% of this activity was 6-AzU; there were 
no other significant peaks. 
Incorporation of radioactivity from 6-AzU and 6-AzUR into 
4 
brain RNA has been reported by Koenig, e_t al. , but with the con¬ 
ditions in this experiment, incorporation of radioactivity was not 
significant. Although radioactivity was detected in one of the RNA 
hydrolysates, the combined data for the four rats showed only 0.0012 
14 
+ 0.0039 micromoles of the label from 2- C-6-azauracil in the RNA 
recovered per 1 gm of we brain tissue. Compared with the total 
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recovery of acid-soluble radioactivity from the brain, this is less 
than 0.1% incorporation into KNA. 
Tissue slices 
The above data raised the question whether the concentrations 
of either 5-AzU or 6-AzUMP in the brain were sufficient to inhibit 
synthesis of uridylic acid. A somewhat equivocal answer was obtained 
14 by measuring the release of radioactive CO2 from 7- C-orotic acid 
by slices of cerebral cortex (Figure 2). This assay is sensitive to 
inhibition of orotidylic acid pyrophosphorylase or orotidylic acid 
decarboxylase. Although in this system both 5-AzU and 6-AzUR did 
inhibit decarboxylation, the later was 100 times more effective. At 
the observed concentration of 5-AzU in brain tissue, inhibition was 
only about 20%. 6-AzUR inhibited decarboxylation by 50% at 3 x 10 
concentration. At 30 times this concentration 6-AzU was ineffective, 
suggesting a much slower rate of conversion to 6-AzUMP. 
14 
Metabolism of 2- C-orotic acid in vivo 
5-AzU, 6-AzU, or saline were administered to rats in the usual 
manner, and at the time when the animals in the group which was given 
6-AzU became comatose (that is, after 1 hour), 0.5 micromoles of 
14 2- C-orotic acid was injected into the cistema magna of all animals 
(the details of this procedure are presented under "Methods"). The 
interpretation of the results requires consideration of several 
incompletely understood variables. 
Since both triazines inhibit the activity of the enzymes between 
orotic acid and uridylic acid (Figur 1), the parameter of interest is 
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the rate of conversion of orotic acid to uridylic acid. A completely 
controlled system for comparison of the inhibition of this conversion 
by 5-AzU or 6-AzUMP have (1) just the two enzymes and co-factors, 
(2) a large (and therefore constant) amount of nonradioactive uri- 
14 
dylic acid, and (3) 2- C-orotic acid, and (4) inhibitor. Although 
accurate determination of this parameter requires more than one 
measurement, an approximation can be made by measuring the extent 
of the (partial) conversion of the radioactive orotic acid to radio¬ 
active uridylic acid in a given period of time. Isotopic dilution 
with carrier orotic acid is a convenient method for measuring the 
amount of radioactive orotic acid which has not been metabolized 
during the reaction period. Acid hydrolysis of the reaction mixture 
before isotopic dilution will add a small amount of radioactivity 
by converting orotidine and orotidylic acid to orotic acid; by 
subtraction of this value from the total radioactivity of the 
reaction mixture, the amount of uridylic acid formed may be calcu¬ 
lated. The reaction from orotidylic acid to uridylic acid is 
4 
essentially irreversible. 
The first two of the above conditions are clearly applicable 
to the situation in the experimental animals. Probably only one 
enzyme, orotidylic acid pyrophosphorylase, is responsible for the 
metabolism of orotic acid in the brain, (see Introduction). There 
is no evidence that orotidine or orotidylic acid are metabolized 
to any product other than uridylic acid or orotic acid. Although 
chromatographic studies did not resolve and identify all the meta- 
14 
bolic products of 2- C-orotic acid, activity associated with 
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dihydroorotic acid was not above background, and there were no 
areas of unexplainable radioactivity. The possibility that 
orotic acid is directly decarboxylated to uracil has been raised. 
However, uracil was only about 20% of the imperfectly resolved 
peak designated as uridine plus uracil. Unless uracil was very 
rapidly lost from brain tissue, any direct contribution from orotic 
acid not passing through uridylic acid would have been quantitatively 
insignificant. The results of the chromatographic analysis of the 
urine of 3 animals in this study support the idea that uracil does 
not enter the general circulation to a significant extent in one 
hour. Over 97% of the radioactivity in the urine of the animals 
14 
administered 5-AzU or 6-AzU was identified as unmetabolized 2- C- 
orotic acid in solvent systems 1 and 2. If the excretion of radio¬ 
active uracil in the urine of these animals had occurred to the 
extent of l/20t^1 of the amount of the sum of uracil and uridine 
recovered in the brain (see figure 2), it would have been detectable. 
On the other hand, only 70 to 75% of the radioactivity in the urine 
14 
of the control animal was 2- C-orotic acid, and 25 to 30% was de¬ 
tected in unidentified metabolites, an amount about equal to only 
about 1/5 of the amount of the sum of uridine and uracil recovered 
from the brain in this animal. In the liver, the pool of uracil is 
29 
relatively large and significant incorporation of radioactivity 
into uridine and uridylic acid from uracil would not be anticipated. 
If the pool of uracil in the brain is also large, then the relative 
increase of the uracil plus uridine peak in comparison with that of 
the uridylic acid and higher phosphate and sugar derivatives in the 
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animals given either triazine was largely attributable to a relative 
increase of uridine, not uracil (Figure 3). 
It is also obvious that uridylic acid was much more abundant 
14 
than 2- C-orotic acid since the concentration of all radioactive 
compounds in the brain was probably only about 0.03 micromoles/gm 
14 
on the average, and the amount of 2- C-orotic acid at any time was 
probably less. The concentration of uridylic acid should have been 
4 
at least 10 times this. Furthermore, there is probably little 
change in the pool of uridylic acid during the experiment, since 
in Koenig's cats, 80% inhibition of orotic acid metabolism by 6-AzUR 
for 3 days resulted in only about a 50% reduction in pool size. 
The third condition presents the most perplexing problem since 
the concentration of endogenous orotic acid, while of considerable 
theoretical importance, is unknown. Although it seems worthwhile 
to consider some of the theoretical effects that this unknown variable 
might have on the comparison of the effects of 5-AzU and 6-AzU, in 
fact there is evidence that the amount of endogenous orotic acid 
is negligible compared to the amount of administered radioactive 
orotic acid. Atempts to measure the pool size of orotic acid in 
various tissues have been unsuccessful; the results of work in this 
, 31 lab indicate that it is less than 0.1 micromoles/gm in liver. 
Isotopic dilution studies using radioactive orotic acid have provided 
indirect evidence that the pools of orotic acid in plasma and in 
38 
tissues are probably small. In one study with rats, the specific 
activity of radioactive orotic acid in the urine was 90% of the 
intraperitoneally injected dose (5.75 micromoles). Equilibration 
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with tissue orotic acid, however, was probably only partial. 
Although orotic acid can enter the general circulation from the 
tissues, as shown by the massive orotic aciduria after blockade of 
orotidylic acid decarboxylase by 6-AzUR in human subjects, the 
amount which normally enters is apparently very small. Plasma 
levels of orotic acid are estimated to be 5 x 10"^ micromoles/ml, 
32 
and urinary excretion is only 1.4 mg/day in human subjects. Since 
blockade of orotidylic acid decarboxylase occurs before the adminis¬ 
tration of radioactive orotic acid, the rate of formation of orotic 
acid in tissues may be of more importance in this study than its 
normal concentration. In comparison with the amount of radioactive 
orotic acid injected into the rats in this study, however, the pro¬ 
duction of endogenous orotic acid is probably very small. The pre- 
4 
viously mentioned study of Koenig, et_ aJ. , indicated that a rela¬ 
tively low rate of synthesis of uridylic acid would maintain the 
pool size in the brain. The concentration of uridylic acid and its 
higher phosphate derivatives decreased from 0.25 to 0.14 micromoles/gm 
in the brain of an animal treated for 3 days with 1 mg of 6-AzUR per 
day by intraventricular injection. This amounts to only 0.0015 micro¬ 
moles/hour, despite the 75 to 87% blockade of the metabolism of 
radioactive orotic acid. The rate of synthesis of pyrimidine bases 
from orotic acid in the adult human subject has been estimated to 
32 53 
be only 600 mg/day, 5 a comparatively small amount. Although it 
is probably the case that accumulation of endogenous orotic acid 
before or after the administration of radioactive orotic acid is 
not significant, several points may in addition be considered as 
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weighing against a significantly different accumulation of orotic 
acid in the two treatment groups. First, the inhibition of its 
metabolism is in either case incomplete, being at most 52% (see 
below). Second, a somewhat circular but still pertinent argument 
is that if the blockade by 6-AzU (after conversion to 6-AzUMP) be¬ 
came significantly greater than that by 5-AzU during the hour afte 
the injection of radioactive orotic acid, then an equivalent and 
compensating accumulation (causing dilution of the radioactive 
orotic acid) would have occurred during this hour as occurred in 
the hour previous to labelling in the 5-AzU treated animals. In 
conclusion, then, orotic acid in fact probably represents a pharma 
cological dose, and not a tracer dose. 
Assuming, then, that the model situation applies to rat brain 
isotopic dilution with orotic acid provides the most important in¬ 
formation about the action of these two inhibitors. Preliminary 
studies showed that orotidylic acid and orotidine are completely 
converted to orotic acid by the acid hydrolysis, and that no signi 
ficant decomposition of orotic acid occurred during similar treat¬ 
ment for one hour. 
One possible explanation of the 60% greater recovery of acid- 
soluble activity from the animals treated with 6-AzU (Figure 3) is 
found in the markedly different distribution of radioactivity in 
these animals. (Table 2). Not only did they produce only a few 
drops of urine, or none, but they also excreted very little of the 
radioactivity in this urine. The animals treated with 5-AzU or 
saline produced at least several milliliters of urine; the animals 
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receiving saline also excreted very little of the radioactivity, 
probably because of the rapid metabolism of orotic acid to nucleo- 
14 
tides in the liver. Respiratory elimination of the C label would 
not have been extensive since the 2-carbon is not released until 
metabolism of uracil to g-alanine. In the animals treated with 
6-AzU the conversion of orotic acid into uridine nucleotides in 
the liver was also blocked. With the major routes of elimination 
and metabolism blocked, the blood and probably cerebrospinal fluid 
levels were increased. It seems likely that hypotension with re¬ 
sulting poor kidney perfusion could explain the decreased urinary 
excretion by these comatose rats, although specific tubular damage 
47 
such as observed from chronic administration of 1 gm/kg of 6-AzUR 
may also have been a factor. 
The results summarized in the first two columns of Figure 3 
show that in control animals the ratio of the sum of orotic acid, 
orotidine, and orotidylic acid to the sum of uridylic acid and all 
other derivatives was 0.17 as compared to 1.1 in rats treated with 
5-AzU and 1.4 in those treated with 6-AzU. Expressed as a percentage 
of radioactive orotic acid undergoing decarboxylation to uridylic 
acid, these values represent 85% + 4%, 47% + 3% and 41% + 5% 
respectively. Inhibition of this conversion was therefore 45% by 
5-AzU, and 52% by 6-AzU. 
The results from paper chromatography did not differ signifi¬ 
cantly from those above in the 12 animals studied (Tables 3 and 4). 
Uridylic acid and derivatives converted to uridylic acid by acid 
hydrolysis were easily distinguishable from uracil and uridine. 
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Chromatographic studies showed that the conditions of the 1 N 
hydrolysis, known to hydrolyze uridine triphosphate and uridine 
63,64 
diphosphate to the monophosphate, caused no significant 
hydrolysis of uridylic acid or uridine. The higher phosphate 
derivatives and the various sugar derivatives together were present 
in the original extract in an amount approximately equal to the 
amount of uridylic acid. The fraction of radioactivity contained 
in orotidine and orotidylic acid together was obtained by subtrac¬ 
tion of the amount found in orotic acid before hydrolysis from that 
found after hydrolysis and was 0.7% + 0.5% in control animals, 
8.3% + 3.1% and 2.4% + 1.8% in animals treated with 5-AzU and 6-AzU. 
These results, though not highly significant statistically, suggest 
that the orotidylic acid decarboxylase is inhibited by 5-AzU, 
and that the formation of orotic acid from orotidylic acid may also 
be inhibited. 
„ 14 
Recovery of radioactivity from 2- C-orotic acid in the hydro¬ 
lyzed ENA fraction varied widely from about 1% to 15%, depending on 
the wash procedure and drug treatment. However, by taking the 
average value of the two control animals in each group, and relating 
the other values to this, the relative incorporation can be calcu¬ 
lated. Normalizing the data to 1.0 + 0.05 for the control animals, 
5-AzU and 6-AzU treated animals were 0.43 + 0.07 and 0.57 + 0.05 
respectively. These compare only approximately to the relative 
activity of uridylic acid and all derivatives which were 1.0 + 0.07, 
0.42 + 0.02 and 0„75 + 0.09 for controls, 5-AzU, and 6-AzU treated 
animals respectively. Incorporation into DNA appeared to be less 
than 5% of that into RNA. 
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CONCLUSIONS 
The experiments described above were designed to test the 
hypothesis that the neurological syndrome caused by 6-AzU is the 
result of "pyrimidine starvation" as a consequence of the inhibition 
of the synthesis of uridylic acid from orotic acid in the brain. 
The supporting evidence for this hypothesis has come from showing 
considerable interdependence of the neurological and pharmacological 
4 5 
effects of the drug. The work of Koenig, e_t all. , and Novotny, et al. , 
in support of this hypothesis has been presented and will be discussed 
in more detail below. It is proposed, however, that the hypothesis 
is incorrect if equivalent inhibition of the synthesis of pyrimidines 
de novo from orotic acid can be demonstrated in the absence of neuro¬ 
logical effects. Demonstration of the converse is less conclusive, 
since the neurological effects are less easily definable. 
In young white rats, the acute effect of 5-AzU was to create a 
metabolic blockade approximately equivalent to that of 6-AzU, but 
without causing observable neurological abnormalities. The drugs were 
administered by the same route; both are known to act principally 
the conversion of orotic acid to uridylic acid in the brain. Inhibi¬ 
tion of this conversion at the time of complete loss of righting 
reflex in the rats treated with 6-AzU was marked, and was approx¬ 
imately equivalent with both drugs. The completeness of the blockade. 
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however, is difficult to estimate, not knowing the certainty of the 
concentration of orotic acid in normal or treated animals. If in 
fact the injected radioactive orotic acid did contribute signifi¬ 
cantly to production of uridylic acid, then the degree of "pyrimidine 
starvation" was greater in the animals treated with 5AzU than in 
those treated with 6-AzU. In addition, the 60% greater amount of 
radioactivity in the brains of the animals treated with 6-AzU may 
have tended to overcome the blockade, making inhibition by 6-AzU 
appear falsely high. There is no evidence to suggest, therefore, 
that 5-AzU is any less effective an inhibitor or orotic acid meta¬ 
bolism in the brain than 6-AzU under the present conditions. The 
hypothesis that the neurological effects result from inhibition of 
orotic acid metabolism or pyrimidine starvation is judged to be 
incorrect in this particular situation. 
One of the central issues is whether the short term (hours) 
and the long term (days) neurological effects are a result of the 
same mechanism. Certainly the basic signs of somnolence, motor 
abnormalities, coma, and characteristic changes in the electro¬ 
encephalogram observed both chronically and acutely in rats, cats, 
and human subjects are basically similar. In adults receiving 
large doses of 6-AzU acutely because of Intestinal breakdown of 
6-AzUR, the neurological effects developed rapidly (within a day)f^ 
Although it cannot be assumed from this that the mechanisms of 
long term and short term toxicity are the same, it remains a pos¬ 
sibility. 
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The unusual sensitivity of the human central nervous system 
to very small doses of 6-AzU is not explained adequately by any 
theory. The wide variability of the responses and the doses of 
6-AzU required to elicit them seems to be a phenomenon limited 
to human subjects. This may in part be attributable to different 
schedules of administration and to different underlying disease 
states. Psychological variability may in part explain some of these, 
but it is difficult to explain how personality structure per se 
could cause variation in such signs as hyperreflexia and coma, or 
electroencephalographic changes. Human subjects differ from animals 
not only in their increased sensitivity to 6-AzU but probably also 
in a decreased sensitivity to the central effects of 6-AzUR. The 
latter effect may possibly be explainable on the basis of poor 
penetration into brain tissue, but it unlikely that 6-AzUR. could be 
more active than 6-AzU in brain tissue of man such as may be the 
case in animals. One would certainly hesitate, however, to admin¬ 
ister this drug intrathecally in patients. 
Although long-term administration of the as-triazines causes 
more marked changes in pyrimidine metabolism than does short-term 
administration, the effect of such interference on brain metabolism 
4 
in general is not know. Koenig, ejt al., suggested that interfer¬ 
ence with the role of uridine and cytidine nucleotides as co-factors 
in sugar, polysaccharide, and phospholipid metabolism might be the 
mechanism causing the disturbance in brain function. It is certainly 
conceivable that the long term depletion of these pools might be 
detrimental to the functioning of the central nervous system, but in 
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what way is not known. There is no report of anatomic lesions in 
the brains of animals treated with 6-AzU. In dogs administered 120 
mg of 6-AzU/day death occurred by the ninth day, but no lesions of 
11,31 
the central nervous system were found on autopsy. In this 
connection, it is also of interest that uridine and cytidine in 
doses of as much as 2.5 gm in human subjects failed to reverse the 
neurological effects of electroencephalographic changes in two pa¬ 
tients with signs of neurological toxicity from 6-AzU. The role 
of RNA is probably less important both neurologically and pharmacolo- 
4 
gically. Koenig, et al., found that the pool of RNA in the brain 
was spared despite the 50% decrease in other pyrimidine pools. 
o 14 
Incorporation of the radioactivity from 2- C-6-AzU over short 
periods of time was not detectable, and incorporation during longer 
periods did not appear to be extensive. Furthermore, inhibition of 
the synthesis of RNA by 95% with actinomycin D in brain appears to 
6 5 have no neurological consequences. 
The studies by Novotny, e_t al. clearly indicate that the 
neurological activity of 6-AzUR is similar to and probably greater 
than that of 6-AzU in mice. To what extent the "antineoplastic" 
activities and the neurological activities of 6-AzU and 6-AzUR 
correspond is a question which deserves further consideration. The 
similarity of the behavioral changes noted after the intraperitoneal 
injection of 6-AzUR to those caused by one-half to one-quarter the 
dose of 6-AzU administered by the same route are certainly convincing, 
and furthermore, the 6-AzUR unquestionably penetrates very poorly into 
brain tissue. That it achieves a concentration in the brain only one 
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thirty-sixth as great as that of 6-AzU, however, seems unlikely. 
With doses of 6-AzUR as great as 10 gm/kg, one might anticipate 
slower elimination by the kidneys and maintainance of high blood 
levels, and consequently relatively greater penetration into the 
brain than the smaller doses of 6-AzU. In addition, the assump¬ 
tion by Novotny, et_ al. that because 6-AzUR is 20 times more 
effective as an anti-neoplastic agent than 6-AzU it must also cause 
20 times as great an inhibition of orotidylic acid decarboxylase in 
rat brain is probably unjustified. Nevertheless, there is little 
doubt that if only one-tenth as much 6-AzUR reached the brain, 
instead of one thirty-sixth, its activity would still be greater 
than that of 6-AzU in mice. There is also no doubt that it would 
be a more active inhibitor of orotidylic acid decarboxylase since 
6-AzU must be converted to 6-AzUR before conversion to 6-AzlIMP. 
Injection of 6-AzUR intracisternally into a cat caused motor inco¬ 
ordination when the concentration of 6-AzUR in brain tissue was 
0.22 to 0.74 micromoles/gm. The concentration of 6-AzU in the brains 
of the comatose rats in this present experiment was 3.1 micromoles/gm 
comparison with the above result suggests that the activities of 
6-AzU and 6-AzUR are at least of the same order of magnitude. 
Although the results of this study suggest no new hypotheses, 
they should by exclusion refocus attention on the barbiturate-like 
properties of the as.-triazines. There is no problem finding both 
similarities and differences in the neurological and pharmacological 
effects of these drugs; for that matter, the barbiturates differ 
among thems elves. 
Structurally 6-AzU resembles the barbiturates. The series of 
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6-alkyl substituted homologs of 6-AzU are even more similar. These 
homologs produce somnolence, and in higher doses, analgesia and 
66 
coma; the motor and psychic abnormalities caused by 6-AzU in 
patients, however, are not seen with the barbiturates. The rela¬ 
tionships among the lipid solubility, the duration of action, the 
rapidity of metabolism, the length of the alkyl side chain, and 
69 
the hypnotic potency seen in a series of barbiturate homo logs 
are also observed with the 5-alkyl substituted triazines (Table 6).^ 
Although lengthening the alkyl substituent increases the hypnotic 
potency of homologs of 6-AzU, none of the homologs has significant 
anti-tumor activity, and presumeably none inhibits orotidylic acid 
decarboxylase. A structural difference between the as-triazines 
and the barbiturates, however, is that the barbiturates require 
both substituents on the 5-carbon for neurological activity whereas 
66 homologs of 6-AzU are active only if there is a single substituent. 
The metabolism of 5-ethyl-6-azauracil is predominantly by oxidation 
to 5-(l-hydroxyethyl)-6-azauracil, and therefore resembles barbitur- 
68 
ate inactivation. Only 1 to 3% of the metabolites recovered in 
the urine are in the form of the ribonucleoside. It is tempting to 
suggest that the increase in neurological activity that occurs with 
the addition of the ribose moiety to 6-AzU is a barbiturate-like 
property. However, the increase in the activity of the barbiturates 
with moderately long alkyl substituents in the 5-position is probably 
a result of increased lipid solubility which increases the amount of 
the drug distributed to the brain. Addition of ribose to 6-AzU, 
however, decreases its penetration into the brain, and presumeably. 
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its lipid solubility. The structure of 5-AzU differs from that of 
6-AzU in having its free carbon atom situated between two nitrogen 
atoms and in this respect is superficially less like the barbiturates. 
Because of the low concentration of 5-AzU in brain tissues, however, 
an accurate estimation of its potential for neurotoxicity cannot be 
made. 
The importance of some of the dissimilarities has probably 
been over-stressed, though certainly there are differences. In 
particular, the electroencephalogram in animals treated with 6-AzU 
and with barbiturates has important similarities as well as differences. 
Neither resembles sleep patterns, and the unusual feature of the 
electroencephalogram after administration of 6-AzU is its resemblance 
to that seen in soma or encephalitis, but at a time when no behavioral 
effect is observable. These changes precede somnolence by several 
days in patients. The onset of electroencephalographic changes after 
barbiturate administration accompanies the somnolence. The changes 
in the electroencephalogram after high doses of barbiturates resemble 
those after 6-AzU administration; both drugs cause large-amplitude 
random slow waves, depression of photic and acoustic responses, 
12,69 
depression of fast activity, and burst-suppression patterns. 
Since most barbiturates have no anti-convulsant activity it is dif¬ 
ficult to asses the significance of the antagonism of 6-AzU to nico¬ 
tine as opposed to pentamethylenetetraazole antagonism seen with bar¬ 
biturates . ^ 
Although the effects of these drugs may be similar in many re¬ 
spects, comparison will be inconclusive as long as the mechanism of 
action of barbiturates is not understood. 
, 
. 
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SUMMARY 
Intraperitoneal injection of 6-azauracil (2 gm/kg) into young 
rats caused complete loss of the righting reflex in about one hour 
while an equimolar amount of 5-azauracil did not appear to effect 
behavior. The concentration of 6-azauracil in the brain one hour 
after the loss of righting reflex was six times that of 5-azauracil 
and metabolites during the equivalent period. At this time the con¬ 
centration of 6-azauridine in the brain was only about 0.7% that of 
the 6-azauracil, and 6-azauridylic acid and glyoxylic acid semi- 
carbazone were even less. Incorporation of the radioactivity from 
14 
2- C-6-azauraci 1 into the RNA of the brain was not significant, and 
was probably less than 0.03% of the total radioactivity in the brain. 
The rate of synthesis of pyrimidine nucleotides by slices of cerebral 
cortex was measured by the release of from 7-^C-orotic acid. 
Concentrations of 5-azauracil in the incubation medium equivalent to 
14 
those observed in vivo significantly slowed the release of CC^ but 
6-azauracil did not. On a molar basis, however, 6-azauridine was 
about one hundred times more effective as an inhibitor of orotic acid 
metabolism than 5-azauracil. The rate of synthesis of pyrimidine 
nucleotides in the brain in vivo was estimated from the extent to 
which ring-labelled orotic acid was converted into uridylic acid 
and its metabolites. Intracisternal injection of the radioactive 
orotic acid was made at the time of complete loss of the righting 
* 
reflex or its equivalent time in the animals administered 5-azauracil 
or saline. In the animals receiving 5-AzU or saline about 10% of the 
injected radioactivity was recovered in an acid extract of the brain 
one hour later; the recovery from the animals receiving 6-AzU was 
about 16%. Analysis of the acid-soluble extract of the brain indicated 
that uracil, uridine, uridylic acid, and sugar and higher phosphate 
derivatives of uridylic acid constituted 85% of the recovered radio¬ 
activity in control animals, but only 41 and 47% in thoss administered 
6-azauracil and 5-azauracil, respectively. These results suggest that 
the loss of the righting reflex, and probably other temporally related 
neurological effects of 6-azauracil are independent of its inhibition 
of the synthesis de novo of pyrimidines in the brain. The neurological 
and pharmacological properties of 6-azauracil and barbiturates are 
compared and the possibility of a barbiturate-like action of 6-azaura¬ 
cil is discussed. 
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TABLE 1. THE CONCENTRATION OF 2- C-5-AZAURACIL AND 2- -C-6- 
AZAURACIL AND THEIR METABOLITES IN THE TISSUES OF THE 
RAT AFTER INTRAPERITONEAL ADMINISTRATION 
Tissue Micromoles of drug/gm wet tissue 
6-azauracil 5-azauracil 
hours after injection* 
1 (2) 2 (4) 1 CD 2 (1) 4 (1) 
whole blood 10.9 9.3 15.1 1.2 0.1 
plasma 12.2 11.2 1.7 0.2 
whole brain 3.1 3.8 0.6 0.6 0.2 
liver 10.7 7.8 2.8 1.2 0.1 
kidney 12.8 13.0 13.0 4.5 0.5 
intestine 9.2 11.9 2.8 1.1 0.1 
spleen 9.1 8.6 3.1 1.1 0.1 
thymus 7.5 6.1 2.5 1.2 0.2 
muscle 3.6 5.8 1.8 0.7 0.1 
The procedure is described in detail under ’’Methods.” 
*The numbers in parentheses indicate the number of rats in 
each group. 
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TABLE 2. THE EFFECT OF PREVIOUS ADMINISTRATION OF 5-AZAURACIL 
AND 6-AZAURACIL ON THE TISSUE DISTRIBUTION OF RADIO¬ 
ACTIVITY AFTER INTRACISTERNAL INJECTION OF 
2-14C-OROTIC ACID 
Pretreatment 
Saline 
5- azauracil 
6- azauracil 
Radioactivity 
Total cpm x 10 
Brain Liver 
_3 
cpm/ml x 10 ' 
Urine Blood 
352 + 55 
318 + 24 
583 + 100 
1140 + 290 
322 + 20 
286 + 25 
108 + 53 
1050 + 200 
50 + 44 
10.4 + 1.2 
13.4 + 2.0 
18.8 + 4.0 
The animals were administered 0.5 micromoles of 2- £ 
acid, 3.3 x 10° cpm, by intracisternal injection 1 hour 
sacrifice. The procedure is described more fully under 
14„ 
C-orotic 
before 
"Methods.' 
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TABIE 3. RESOLUTION OF SEIECTED PYRIMIDINES AND TRIAZINES 
IN THREE SOLVENT SYSTEMS 
Compound Rf x 100 
Solvent systems 
(1) (2) (3) 
6-Azauracil 59 71 63 
6-Azauridine 40 63 50 
6-Azauridylic acid 13 14 28 
Glyoxylic acid semicarbazone 52 36 41 
5-Azauracil 43 63 -- 
Dihydroorotic acid 34 35 - « 
Orotic acid 25 50 30 
Orotidine 18 42 29 
Orotidylic acid 8 12 14 
Uridylic acid 16 20 30 
Uridine diphosphate 9 17 -- 
Uridine triphosphate 6 14 -- 
Uridine diphosphate glucose 6 24 12 
Uridine diphosphate glucosamine 6 28 16 
Uridine 42 73 60 
Uracil 54 70 69 
The solvent systems are: (1) n-butanol, glacial acetic 
acid, and water, 5:1:2; (2) n-butanol, pyridine, and water, 
1:1:1; and (3) iso-butyric acid, 2 N ammonium hydroxide, and 
water, 85:1.3:15. 
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TAB IE 4. COMPARISON OF THE DATA OBTAINED BY PAPER CHROMATOGRAPHY 
(TABIE 4) TO THOSE OBTAINED BY ISOTOPIC DILUTION 
Pretreatment Percentage of the total radioactivity of the 
acid extract of brain present as orotic acid 
after acid hydrolysis. 
By paper 
chromatography 
(average) By isotopic dilution 
Saline 14.7 + 4.9 (4) 14.3 + 3.5 (4) 14.9 + 4.4 (6) 
5-Azauracil 54.7 + 5.0 (4) 55.1 + 2.0 (4) 52.8 + 3.3 (8) 
6-Azauracil 60.6 + 2.6 (4) 60.9 + 3.7 (4) 58.5 +4.7 (7) 
The numbers in parentheses indicate the number of animals in 
each group; the data in the first two columns are from the same 
animals; the third column shows the result for all 21 animals. 

TAB IE 5. COMPARISON OF HYPNOTIC POTENCY AND PHARMACOLOGICAL 
PROPERTIES OF 6-AZAURACIL AND ALKYL DERIVATIVES* 
Relative Time of 
mo lar onset of 
potency hypnosis 
Compound in mice in min. 
6-Azauracil 1.0 45-60 
5-Methy1-6- 
azauracil 2.7 20-30 
5-Ethyl-6- 
azauracil 5.0 18-20 
5-Propyl-6- 
azauracil 8.2 8-12 
Re lative 
distri¬ 
bution 
coefficient 
EtAcrpH 7.3 
buffer 
* 
Duration 
of hypnosis 
in hours 
Percent 
Me tab - 
olized 
in 24 
hours 
1.0 4-8 0-10 
3.1 2-3 20 
7.9 hr 1 73 
12.1 %-2 87 
Unpublished data of R. E. HandSchumacher. 
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Figure 1. Summary of pyrimidine metabolism in mammals and the 
action of 6-azauracil. Abbreviations: USA, ureidosuccinic acid; 
DHOA, dihydroorotic acid; OA, orotic acid; OR, orotidine; OMP, 
orotidylic acid; PRPP, 5-phosphoribosyl-l-pyrophosphate; PP, 
inorganic pyrophosphate; UMP, uridylic acid; UR, uridylic acid; 
U, uracil; UUP, uridine diphosphate; dUDP, deoxyuridine diphos¬ 
phate; dUMP, deoxyuridine monophosphate; UTP, uridine triphos¬ 
phate; CTP, cytidine triphosphate; CDP, cytidine diphosphate; 
dCDP, deoxycytidine diphosphate; dCTP, deoxycytidine triphosphase; 
TMP, thymidine monophosphate; TDP, thymidine diphosphate; TTP, 
thymidine triphosphate; UDPX, uridine diphosphate sugar deriva¬ 
tives; CDPX, cytidine diphosphate sugar derivatives. 
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Figure 2. The effect 5-azauraci j.. 6-azauracil, and 6-azauri- 
dine on the release of CO2 from 7- u-orotic acid, 0.05 micro¬ 
moles/ml, by tissue slices from the cerebral cortex of rats, 30 
min. incubation. Each symbol represents a single determination. 
The mean value and standard deviation is indicated for 9 control 
animals. 
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Figure 3. The effect of 5-azauracil, 2g/kg, and 6-azauracil, 
2g/kg, on the metabolism of 7-^C-orotic acid (0.45 micromoles, 
3.3 x 10^ cpm) administered into the cisterna magna of rats. 
The numbers in parentheses indicate the number of animals in 
each group. Abbreviations are defined on p. 15. The procedure 
is described under "Methods.1' 
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